Celldex Therapeutics, Inc.CLDX

Market cap

$2.1B

P/E ratio

	Dec 31, 2011	Dec 31, 2012	Dec 31, 2013	Dec 31, 2014	Dec 31, 2015	Dec 31, 2016	Dec 31, 2017	Dec 31, 2018	Dec 31, 2019	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023
Service	-	-	-	-	-	-	-	3	0	2	0	0	0
Grant	-	-	-	-	-	-	-	6	3	5	5	2	7
Total revenues	9	11	4	4	-	-	-	10	4	7	5	2	7
Research and development	32	47	67	104	-	-	-	66	43	43	53	82	118
General and administrative	9	10	15	21	-	-	-	19	15	14	20	27	31
Intangible asset impairment	-	-	-	-	-	-	13	-	-	18	4	-	-
Gain on fair value remeasurement of contingent consideration	-	-	-	-	-	-	-	-	1	4	1	7	-
Litigation settlement related loss	-	-	-	-	-	-	-	-	-	-	-	-15	-12
Total operating expenses	53	69	86	126	-	-	-	166	59	71	76	118	161
Operating loss	-43	-58	-81	-122	-	-	-	-156	-55	-63	-71	-115	-155
Interest and Other Income	-	1	1	4	-	-	-	4	4	2	1	3	13
Net loss before income tax benefit	-45	-	-	-	-	-	-	-152	-51	-61	-71	-112	-141
Income tax benefit	-	-	-	-	-	-	-24	-1	-	-1	-0	-	-
Net loss	-45	-59	-82	-118	-127	-129	-93	-151	-51	-60	-71	-112	-141
Earnings Per Share, Basic	-	-	-	-	-	-	-	-	-	-	-1.64	-2.4	-2.92
Earnings Per Share, Diluted	-	-	-	-	-	-	-	-	-	-	-1.64	-2.4	-2.92
Net loss	-45	-59	-82	-118	-127	-129	-93	-151	-51	-60	-71	-112	-141
Unrealized gain (loss) on marketable securities	-0	0	-0	-0	-	-	-	0	0	-0	-1	-1	2
Comprehensive loss	-45	-59	-82	-118	-	-	-	-151	-51	-60	-71	-113	-139